Drug Enforcement D-0155-2025

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Status

Ongoing

Classification

Class II

Report Date

January 1, 2025

Termination Date

—

Product Information

Product description
Duloxetine Delayed-Release Capsules USP, 30 mg, Rx only, 30 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-04
Product quantity
21,262 bottles
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
Recall initiation reason
—
Initial firm notification
Letter
Distribution pattern
Nationwide in the USA

Location & Firm

Recalling firm
Amerisource Health Services LLC
Address
2550 John Glenn Ave Ste A

United States
Voluntary / Mandated
Voluntary: Firm initiated
Status date
—

Codes & Dates

Recall number
D-0155-2025
Event ID
95953
Recall initiation date
December 6, 2024
Center classification date
December 23, 2024
Code info
Lot DT3023029A Exp 02/28/2025
More code info
—